{
    "clinical_study": {
        "@rank": "31701", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }, 
            {
                "arm_group_label": "Active, nadolol", 
                "arm_group_type": "Experimental", 
                "description": "Active"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to test the hypothesis that 18\u201422 week treatment with the\n      inverse agonist nadolol will improve airway hyperresponsiveness in patients with mild\n      asthma, compared to placebo."
        }, 
        "brief_title": "Efficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol, in Mild Asthma", 
        "condition": "Mild Persistent Asthma, Uncomplicated", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Individuals who meet all of the following criteria are eligible for enrollment as study\n        participants:\n\n        1. Males and females with physician-diagnosed asthma between the ages of 18- 60.\n\n        2. Pre-bronchodilator FEV1 80% or greater than the predicted value\n\n        3. Baseline PC20 (based on FEV1) \u2264 4 mg/ml on methacholine challenge test.\n\n        4. Asthma Control Questionnaire Score (ACQ) <1.25\n\n        5. Baseline blood pressure \u2265 110/65mm Hg\n\n        6. Baseline pulse rate \u2265 60 beats/min.\n\n        7. Never-smoker or former-smoker < 10 pack.year and has not smoked within 1 year.\n\n        8. Able to complete diary cards and comply with study procedures.\n\n        9. Females of childbearing age may participate only if they have a negative pregnancy\n        test, are non-lactating, and agree to practice an adequate birth control method\n        (abstinence, combination barrier and spermicide, or hormonal) for the duration of the\n        study.\n\n        Exclusion Criteria:\n\n        Subjects who meet ANY of the following criteria are not eligible for enrollment:\n\n          1. Inability or unwillingness of the participant to give written informed consent\n\n          2. History of upper/lower respiratory tract infection or asthma exacerbation requiring\n             systemic steroids within 6 weeks of Visit 1\n\n          3. Use of rescue medication (e.g., albuterol) more than twice per week during the week\n             preceding Visit 1 excluding the use of such medication as preventative prior to\n             exercise.\n\n          4. History of hospitalization for asthma in the preceding year\n\n          5. History of intubation for asthma\n\n          6. Currently diagnosed with chronic obstructive pulmonary disease (COPD)\n\n          7. Currently taking any beta-blocker medication\n\n          8. History of adverse reaction or allergy to any beta-blocker medication\n\n          9. History of neurological, hepatic, renal, or other medical conditions that may\n             interfere with the interpretation of data or the patient's participation in the study\n             or may increase safety concerns\n\n         10. Current diabetes or hyperthyroidism\n\n         11. History of cardiovascular diseases including uncontrolled hypertension (BP >160/100),\n             ischemic heart disease, congestive heart failure, valvular heart disease or\n             cardiomyopathy\n\n         12. Known allergy or sensitivity to atropine or ipratropium bromide\n\n         13. Abnormal entry laboratory values at baseline except for the following tests, where\n             values outside the normal limits will be acceptable as follows: Hct \u2265 30%, platelet\n             count > 100,000, ALT and AST < 1.5 x upper normal limit\n\n         14. Known bleeding disorders, platelet count <100,000, PT or PTT > 1.5 x normal control\n             (if participating in bronchoscopy sub-study)\n\n         15. Known allergy to lidocaine (if participating in bronchoscopy sub-study)\n\n         16. Documented or self-reported current history of alcoholism or drug abuse\n\n         17. Participation in another research trial within 30 days of starting this trial\n\n         18. Unwillingness or inability to comply with study procedures\n\n         19. Inability to swallow the study medication capsule\n\n         20. Use of any exclusion medication within the time period specified\n\n         21. Pregnant or nursing\n\n         22. Receiving allergen immunotherapy (desensitization injections)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01804218", 
            "org_study_id": "U01-BCM-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Active, nadolol", 
                "intervention_name": "Nadolol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Nadolol"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 12, 2014", 
        "location": [
            {
                "contact": {
                    "email": "bxpatter@dom.wustl.edu", 
                    "last_name": "Brenda Patterson, MSN, RN, FNP", 
                    "phone": "314-362-3849"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University School of Medicine"
                }, 
                "investigator": [
                    {
                        "last_name": "Kaharu Sumino, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Mario Castro, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Ajay Sheshadri, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Adrian Shifren, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Brenda Patterson, RN, MSN, FNP", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "holly.monroe@duke.edu", 
                    "last_name": "Holly Monroe", 
                    "phone": "919-479-0743"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27704"
                    }, 
                    "name": "Duke University Medical Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Monica Kraft, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Divya Bappanad, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Njira Lugogo, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Loretta Que, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Isaretta Riley, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mbrock@bcm.edu", 
                    "last_name": "Melissa Brock, RN", 
                    "phone": "713-873-8772"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Baylor College of Medicine"
                }, 
                "investigator": [
                    {
                        "last_name": "Nicola A. Hanania, MD, MS", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Venkata Bandi, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Goutham Dronavalli, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Amit Parulekar, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "hanania@bcm.edu", 
            "last_name": "Nicola Hanania, MD, MS", 
            "phone": "713-873-3454"
        }, 
        "overall_official": {
            "affiliation": "Baylor College of Medicine", 
            "last_name": "Nicola A. Hanania, MD, MS", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board", 
                "United States: Data and Safety Monitoring Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The change in methacholine provocative concentration causing a 20% fall (PC20) based on forced expiratory volume in 1 second (FEV1) between baseline visit and final dose dispensing visit.", 
            "safety_issue": "No", 
            "time_frame": "4 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01804218"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Invion, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Invion, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}